InSysBio to take part in ACoP 2024

2 1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

5 1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.

8 1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

12 1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.

17 1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.

22 1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website

30 1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

events

Conference

September 11, 2024

InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP) which is to be held from November 10-13, 2024, at the Arizona Grand Resort & Spa in Phoenix, Arizona, USA. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin" on Tuesday, November 12, 2:00 PM – 3:30 PM MST, Location: Kaibab & Lantana. Oleg will give a talk "QSP modeling of engineered autologous T-cell therapies: random virtual patients vs virtual twins” at 2:20 PM – 2:40 PM MST in frames of the session.

InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference, namely:

Monday, November 11, 7:00 AM – 5:00 PM MST:

M-024 "Mechanistic translational modeling versus minimal anticipated biological effect level approach to predict first-in-human dose for T-cell engagers: HPN536 case study" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov

Tuesday, November 12, 7:00 AM – 5:00 PM MST:

T-047 "FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines" by Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin

Wednesday, November 13, 7:00 AM – 1:45 PM MST:

W-004 "Development of QSP model of non-small cell lung cancer and its application to select optimal dose for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1" by Gaurav Bajaj¹, Alexandra Diakonova², Sergey Smirnov², Anna Roskoshnaia², Ivan Borisov², Patricia Garrido Castro³, Nora Pencheva³, Maria Jure-Kunkel¹, Beesan Tan⁴, Tim Maiwald⁴, Manish Gupta¹, Oleg Demin⁵, Craig Thalhauser¹

Affiliation: (1) Genmab, Plainsboro, NJ, USA; (2) InSysBio CY, Paphos, Cyprus; (3) Genmab Utrecht, Netherlands; (4) BioNTech SE, Mainz, Germany; (5) InSysBio UK, Edinburgh, UK

W-005 "Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection" by Gaurav Bajaj¹, Dmitry Shchelokov², Oleg Demin Jr², Homer Adams III¹, Summer Feng¹, Leonid Gibiansky³, Saskia van der Lee⁴, Anandhi Johri¹, Alexander Muik⁵, Porntula Panorchan⁵, Manish Gupta¹, Oleg Demin⁶, Craig Thalhauser¹

Affiliation: (1) Genmab, Plainsboro, NJ, USA; (2) InSysBio CY, Limassol, Cyprus; (3) QuantPharm LLC, North Potomac, MD, USA; (4) Genmab, Utrecht, The Netherlands; (5) BioNTech SE, Mainz, Germany; (6) InSysBio UK, Edinburgh, UK

W-006 "Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab" by Evgeny Metelkin¹, Ivan Borisov¹, Sergey Smirnov¹, Oleg Demin², Gaurav Bajaj³, Jordan Blum³, Maria Jure-Kunkel³, Beesan Tan⁴, Tim Maiwald⁴, Manish Gupta³, Craig Thalhauser³

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, NJ, (4) BioNTech SE, Mainz, Germany

W-060 "Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients" by Tatiana Karelina, Oleg Demin, Dmitry Gordeev, Mariia Myshkina
W-061 "Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes" by Tatiana Karelina¹, Valeriu Damian², Oleg Demin³, Stepan Lerner¹, Polina Maliukova¹, Mahadevabharath Somayaji², Olga Ivanova¹

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) GSK, Collegeville, PA, US; (3) InSysBio UK, Edinburgh, UK

W-072 "Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database" by Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
W-107 “Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions" by Ruslan Salimgareev¹, Oleg Demin Jr², Oleg Demin³

Affiliation: (1) Lomonosov Moscow State University, Moscow, Russia; (2) InSysBio CY, Paphos, Cyprus; (3) InSysBio UK, Edinburgh, UK

Check out our posters and Booth #11 at ACoP 2024!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

←	June 2020	→
Mo	Tu	We	Th	Fr	Sa	Su
1	2 1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.	3	4	5 1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.	6	7
8 1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.	9	10	11	12 1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.	13	14
15	16	17 1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.	18	19	20	21
22 1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website	23	24	25	26	27	28
29	30 1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Upcoming Events